Compare TJX Companies Inc (TJX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? TJX Companies Inc trades at $138.79 (market cap $152.62B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: TJX Companies Inc is the larger of the two by market cap, and TJX Companies Inc pays a 1.38% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold TJX Companies Inc for 97 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TJX | VRTX | |
|---|---|---|
Market Cap | $152.62B | $127.55B |
Volume | 8,079,794 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $557.96 |
52-Week Low | $122.84 | $407.37 |
Typical Hold Time | 97 Days | 120 Days |
Enterprise Value | $160.93B | $121.68B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $138.80, up 1.28% today, with a bullish technical trend and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.33. Revenue grew to $56.36B in 2025, with a net income margin of 8.63%. Analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 25% upside. Recent news highlights TJX's value proposition and merchandising strength in the off-price retail sector.
TJX presents a compelling investment opportunity driven by earnings growth, high profitability (ROE 62.17%), and positive analyst sentiment. Risks include competitive pressures, economic sensitivity, and valuation multiples above industry averages. The stock's momentum and fundamental strength support a favorable outlook, but investors should monitor execution against future earnings expectations.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
